Back to top
more

Novartis (NVS)

(Real Time Quote from BATS)

$118.62 USD

118.62
90,930

+0.12 (0.10%)

Updated Sep 4, 2024 10:12 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (61 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Incyte Gets FDA Nod for Cholangiocarcinoma Drug Pemazyre

by Zacks Equity Research

Incyte (INCY) gets FDA approval for Pemazyre for the treatment of previously-treated, unresectable, locally-advanced or metastatic cholangiocarcinoma.

Sweta Jaiswal, FRM headshot

ETFs to Rise as Gilead Drug Shows Promise in Coronavirus Cure

by Sweta Jaiswal, FRM

Gilead Sciences (GILD) has ignited a ray of hope with its recently-released positive data on the role of remdesivir as a COVID-19 treatment.

Alnylam's $2B Deal With Blackstone to Boost Drug Development

by Zacks Equity Research

Alnylam (ALNY) and Blackstone sign a collaboration deal per which Blackstone will invest up to $2 billion in Alnylam. The funds will support accelerated development of Alnylam's pipeline.

Bausch (BHC) Starts Study on Virazole for Coronavirus Infection

by Zacks Equity Research

Bausch (BHC) begins a clinical study on Virazole in combination with standard-of-care therapy to treat adults with respiratory distress due to COVID-19 in Canada.

Roche's NDA for SMA Drug Gets Expanded Review From FDA

by Zacks Equity Research

The FDA stretches the review timeline of Roche's (RHHBY) NDA for risdiplam by three months, which is being evaluated to treat spinal muscular atrophy. A decision is now pending on Aug 24, 2020.

Alnylam (ALNY) Completes Rolling Submission of Lumasiran NDA

by Zacks Equity Research

Alnylam (ALNY) completes rolling submission of the NDA for lumasiran seeking approval for kidney disease, primary hyperoxaluria type 1. The EMA accepts MAA for lumasiran for the same indication.

Kinjel Shah headshot

Large-Cap Pharma Stocks to Benefit in Post-Pandemic Market

by Kinjel Shah

The Zacks Large Cap Pharmaceuticals industry ranks in the top 13% of more than 250 Zacks industries.

Sweta Jaiswal, FRM headshot

Biotech Stocks, ETFs to Gain on COVID-19 Vaccine & Drug Progress

by Sweta Jaiswal, FRM

The race to introduce a vaccine and drug for COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.

Immunomedics Up as Breast Cancer Drug Study Shows Efficacy

by Zacks Equity Research

Immunomedics (IMMU) soars as the phase III study on breast cancer drug shows efficacy and will be subsequently halted.

The Zacks Analyst Blog Highlights: Johnson & Johnson, Merck & Co, Novartis, PayPal and IBM

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Johnson & Johnson, Merck & Co, Novartis, PayPal and IBM

Bristol Myers/Acceleron's Reblozyl Label Expansion Gets FDA Nod

by Zacks Equity Research

Bristol Myers (BMY) and Acceleron received FDA nod for the label expansion of Reblozyl for MDS patients who require RBC transfusions, failing an erythropoiesis stimulating agent.

Sheraz Mian headshot

Top Stock Reports for J&J, Merck, Novartis & Others

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Merck (MRK) and Novartis (NVS).

Kinjel Shah headshot

Pharma Coronavirus Efforts Continue, Amgen & Incyte Join In

by Kinjel Shah

Amgen (AMGN) signs a deal with Adaptive Biotechnologies to discover antibodies to prevent/treat COVID-19. Incyte/Novartis (NVS) plan to initiate study on Jakafi for COVID-19- associated cytokine storm.

Novartis Terminates Sale of Sandoz Dermatology Business

by Zacks Equity Research

Novartis (NVS) terminates sale of Sandoz US generic oral solids and dermatology businesses to Aurobindo Pharma USA Inc.

NVS vs. NVO: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

NVS vs. NVO: Which Stock Is the Better Value Option?

The Zacks Analyst Blog Highlights: Novartis, Teva, Gilead and AbbVie

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Novartis, Teva, Gilead and AbbVie

Lilly's Taltz Gets FDA Nod for Plaque Psoriasis in Children

by Zacks Equity Research

The FDA approves Eli Lilly's (LLY) sBLA for Taltz injection to treat pediatric patients with moderate to severe plaque psoriasis. Stock up.

Sejuti Banerjea headshot

COVID-19 Claiming Lives But Therapeutics Could Be on the Way

by Sejuti Banerjea

The WHO's Solidarity testing project could be good news for the world.

Novartis Reports Data on Inclisiran, CHMP Positive on Zolgensma

by Zacks Equity Research

Novartis (NVS) announces pipeline updates on inclisiran and regulatory updates on Cosentyx and Zolgensma.

Jazz's (JAZZ) Xyrem Follow-On Candidate NDA Gets FDA Acceptance

by Zacks Equity Research

The FDA accepts Jazz's (JAZZ) regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem in the United States.

Novartis to Donate Generic Hydroxychloroquine for Coronavirus

by Zacks Equity Research

Novartis (NVS) will donate 130 million doses of generic hydroxychloroquine for COVID-19 treatment.

Aduro's (ADRO) Earnings & Revenues Miss Estimates in Q4

by Zacks Equity Research

Aduro (ADRO) incurs wider-than-expected loss in Q4. Revenues too fall short of the mark.

Puma Biotech's (PBYI) Nerlynx Aids Growth Despite Competition

by Zacks Equity Research

Puma Biotech (PBYI) focuses on improving sales of its only marketed drug Nerlynx, which is approved for treating breast cancer. High dependence on Nerlynx for growth remains a woe.

AMAG Sees High Feraheme Sales, To Sell Women Healthcare Drugs

by Zacks Equity Research

AMAG (AMAG) plans to divest two of its women healthcare drugs, Intrarosa and Vyleesi. Its marketed drug, Feraheme, achieves record sales in 2019.

J&J Files MAA for Multiple Sclerosis Drug Ponesimod in Europe

by Zacks Equity Research

Ponesimod's regulatory application in Europe is based on data from the head-to-head OPTIMUM phase III study comparing it to Sanofi's (SNY) MS drug, Aubagio